- Consider speaking
to your healthcare professional about the maraviroc EAP.
Maraviroc is an investigational drug being developed for use in combination
antiretroviral medications for the treatment of human immunodeficiency
virus, type-1 (HIV-1)
infected treatment-experienced patients.
- This table summarizes how
to apply for two expanded access programs: MK 518-
Merck's integrase inhibitor and TMC 125- Tibotec's non nucleoside analog.
need adobe acrobat reader to open the file ( you can get free adobe
This is the table
- EXPANDED ACCESS PROGRAM
(EAP) IN THE USA
Tibotec has opened its expanded access program (EAP) for its investigational
non-nucleoside reverse transcriptase inhibitor (NNRTI), TMC125, in the
program will provide access for HIV-1 infected patients who need the
construct a viable treatment regimen.
Therapeutics, a division of Ortho Biotech Products, L.P.
- Enrollment Is Open to Early Access Program for
Experimental HIV Protease Inhibitor TMC114 with
Ritonavir in HIV Patients with Limited Treatment
This is an open-label safety study to provide early
access to the promising experimental HIV protease
inhibitor TMC114 for patients who have failed and
exhausted regimens based on currently available
anti-HIV therapy and who are ineligible for
participation in any other Tibotec-sponsored trial of
TMC 114. Full article: